tetano
Editor, Senior Moderator
Kidney Res Clin Pract
. 2024 Feb 19.
doi: 10.23876/j.krcp.23.121. Online ahead of print. Anti-SARS-CoV-2 spike antibody response to the third dose of BNT162b2 mRNA COVID-19 vaccine and associated factors in Japanese hemodialysis patients
Keiji Hirai[SUP] 1 [/SUP], Masako Shimotashiro[SUP] 2 [/SUP], Toshiaki Okumura[SUP] 2 [/SUP], Susumu Ookawara[SUP] 1 [/SUP], Yoshiyuki Morishita[SUP] 1 [/SUP]
Affiliations
Background: We assessed the anti-SARS-CoV-2 spike antibody response to the third dose of BNT162b2 mRNA COVID-19 vaccine in Japanese hemodialysis patients and determined factors associated with the anti-SARS-CoV-2 spike antibody titer after the third dose of COVID-19 vaccine.
Methods: Overall, 64 patients (37 males, 27 females; mean age 71.4 ± 11.7 years) were enrolled in this single-center, prospective, longitudinal study. Anti-SARS-CoV-2 spike antibody titers were compared between hemodialysis patients and 18 healthcare workers (8 males, 10 females; mean age 45.9 ± 12.2 years). Multiple linear regression analysis was used to identify factors associated with the anti-SARS-CoV-2 spike antibody titer after the third vaccination.
Results: There was no significant difference in anti-SARS-CoV-2 spike antibody titer 4 weeks after the third vaccination between hemodialysis patients and healthcare workers (18,500 [interquartile range, 11,000-34,500] vs. 11,500 [interquartile range, 7,918-19,500], all values in AU/mL; p = 0.17). Uric acid (standard coefficient [β] = -0.203, p = 0.02), transferrin saturation (β = -0.269, p = 0.003), and log-anti-SARS-CoV-2 spike antibody titer 1 week before the third vaccination (β = 0.440, p < 0.001) correlated with the log-anti-SARS-CoV-2 spike antibody titer 4 weeks after the third vaccination. In contrast, only the log-anti-SARS-CoV-2 spike antibody titer 1 week before the third vaccination (β = 0.410, p < 0.001) correlated with the log-anti-SARS-CoV-2 spike antibody titer 12 weeks after the third vaccination.
Conclusion: The anti-SARS-CoV-2 spike antibody titer after the third dose of COVID-19 vaccine was comparable between hemodialysis patients and healthcare workers. Uric acid concentration, transferrin saturation, and anti-SARS-CoV-2 spike antibody titer before the third dose were associated with the anti-SARS-CoV-2 spike antibody titer after the third dose in Japanese hemodialysis patients.
Keywords: Anti-severe acute respiratory syndrome coronavirus 2 spike antibody; BNT162b2 messenger RNA vaccine; COVID-19; Hemodialysis; SARS-CoV-2.
. 2024 Feb 19.
doi: 10.23876/j.krcp.23.121. Online ahead of print. Anti-SARS-CoV-2 spike antibody response to the third dose of BNT162b2 mRNA COVID-19 vaccine and associated factors in Japanese hemodialysis patients
Keiji Hirai[SUP] 1 [/SUP], Masako Shimotashiro[SUP] 2 [/SUP], Toshiaki Okumura[SUP] 2 [/SUP], Susumu Ookawara[SUP] 1 [/SUP], Yoshiyuki Morishita[SUP] 1 [/SUP]
Affiliations
- PMID: 38389151
- DOI: 10.23876/j.krcp.23.121
Background: We assessed the anti-SARS-CoV-2 spike antibody response to the third dose of BNT162b2 mRNA COVID-19 vaccine in Japanese hemodialysis patients and determined factors associated with the anti-SARS-CoV-2 spike antibody titer after the third dose of COVID-19 vaccine.
Methods: Overall, 64 patients (37 males, 27 females; mean age 71.4 ± 11.7 years) were enrolled in this single-center, prospective, longitudinal study. Anti-SARS-CoV-2 spike antibody titers were compared between hemodialysis patients and 18 healthcare workers (8 males, 10 females; mean age 45.9 ± 12.2 years). Multiple linear regression analysis was used to identify factors associated with the anti-SARS-CoV-2 spike antibody titer after the third vaccination.
Results: There was no significant difference in anti-SARS-CoV-2 spike antibody titer 4 weeks after the third vaccination between hemodialysis patients and healthcare workers (18,500 [interquartile range, 11,000-34,500] vs. 11,500 [interquartile range, 7,918-19,500], all values in AU/mL; p = 0.17). Uric acid (standard coefficient [β] = -0.203, p = 0.02), transferrin saturation (β = -0.269, p = 0.003), and log-anti-SARS-CoV-2 spike antibody titer 1 week before the third vaccination (β = 0.440, p < 0.001) correlated with the log-anti-SARS-CoV-2 spike antibody titer 4 weeks after the third vaccination. In contrast, only the log-anti-SARS-CoV-2 spike antibody titer 1 week before the third vaccination (β = 0.410, p < 0.001) correlated with the log-anti-SARS-CoV-2 spike antibody titer 12 weeks after the third vaccination.
Conclusion: The anti-SARS-CoV-2 spike antibody titer after the third dose of COVID-19 vaccine was comparable between hemodialysis patients and healthcare workers. Uric acid concentration, transferrin saturation, and anti-SARS-CoV-2 spike antibody titer before the third dose were associated with the anti-SARS-CoV-2 spike antibody titer after the third dose in Japanese hemodialysis patients.
Keywords: Anti-severe acute respiratory syndrome coronavirus 2 spike antibody; BNT162b2 messenger RNA vaccine; COVID-19; Hemodialysis; SARS-CoV-2.